44 results about "Tazarotene" patented technology

An improved method and preparation for the treatment of acne and hirsutism comprises topically applying an effective amount of a saw palmetto berry extract, and preferably one or more low irritability constituents that enhance penetration of the extract into hair follicle sebaceous glands. The low irritability penetration aid may be selected from the group consisting of adapalene, tretinoin, tretinoin gel microsponges, retinaldehyde, retinol, tazarotene, beta hydroxy acids (salicylic acid), azelaic acid, and alpha hydroxy acids (glycolic acid) as well as polyolprepolymer-2.

An improved method and preparation for the treatment of acne and hirsutism comprises topically applying an effective amount of a saw palmetto berry extract, in combination with two classes of low irritability penetrating agents that enhance penetration of the extract into hair follicles and sebaceous glands. The low irritability penetration agents are selected from the group (A) comedolytics consisting of adapalene, tretinoin, tretinoin gel microsponges, retinaldehyde, retinol, and tazarotene, and (B) keratinolytics consisting of the beta hydroxy acid, salicylic acid, and the alpha hydroxy acid, glycolic acid. Polyolprepolymer-2 may be incorporated into the preparation as well.

The present invention relates to a compound medicine for external application for curing acne. Its composition contains the following two active components: (wt%) 0.01-2% of tazarotene and 0.25-5% of antimicrobial. Said compound medicine can be made into emulsifiable paste or gel or liniment or film preparation. Said compound medicine has the following therapeutic functions: dissolving keratotic plug, regulating keratosis, resisting microbe, relieving inflammation and reducing secondary factor of sebaceous secretion, so that it can obtain obvious therapeutic effect.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

The present invention relates to a compound medicine for external application for curing psoriasis. It is characterized by that in the matrix carrier of said compound medicine for external application are contained the following effective active components: (wt%) tazarotenje 0.025-0.1% and cortical hormone 0.01-0.2%. Its therapeutic effect is good, and it has no adverse reaction.

A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.

Tazarotene is prepared by deoxygenation of the corresponding S-oxide, in turn obtained according to two alternative synthetic pathways.

A composite medicine in the form of ointment and gels for treating psoriasis contains Tazhuluoding, betamethasone dipropionate and pharmacologically receptable auxiliary. Its advantages are high curative effect and high safety.

A topical composition which includes a silica microspheres and an active ingredient in the amount of 0.01 to 15.0% w / w wherein the active ingredient is selected from adapalene, an antibiotic, tazarotene, tretinoin, a retinoid, or any combination thereof. The topical composition may also include benzoyl peroxide as an active ingredient. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

The present invention provides a method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid. This invention is especially useful for treating psoriasis.

Tazarotene is prepared by deoxygenation of the corresponding S-oxide, in turn obtained according to two alternative synthetic pathways.

An improved process for the preparation of key intermediates for tazarotene, 4,4-dimethyl-6-ethynylthiochroman, is provided comprising (a) reacting 4,4-dimethyl-6-acetylthiochroman of the formula with an acid chloride and an amido-group containing compound of the general formula wherein R is hydrogen or a hydrocarbyl of from 1 to 15 carbon atoms and R1 and R2 can be the same or different and are hydrocarbyls of from 1 to 15 carbon atoms or R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a heterocyclic group, optionally containing one or more additional heterocyclic atoms, or one of R1 and R2 together with the nitrogen atom to which it bonded are joined together with the carbonyl radical to form a heterocyclic group, optionally containing one or more additional heterocyclic atoms to form a β-chloro vinyl carbonyl compound intermediate of the general formula wherein R has the aforestated meanings; and (b) reacting the β-chloro vinyl carbonyl compound intermediate with an alkali metal to provide the 4,4-dimethyl-6-ethynylthiochroman.

Topical compositions for dermatological use are described. The topical compositions generally comprise a selective retinoid, such as tazarotene or adapalene, and / or a tetracycline-class antibiotic, such as minocycline or doxycycline, and a monohydric aliphatic alcohol. The compositions may further comprise a divalent cation, such as magnesium, calcium, or zinc, and an antioxidant, such as a sulfite or a thiosulfate. The composition may further comprise a carboxylate ester solvent.

The present invention belongs to the field of analytical chemistry, and relates to a method for separation and determination of two medicine contents and related substances in a tazarotene-betamethasone cream. According to the method, a reagent composition for solid-liquid separation and determination of two medicine contents and related substances in a tazarotene-betamethasone cream comprises an acidic aqueous solution system and acetonitrile, wherein the acidic aqueous solution system comprises an acidic additive, methanol and water; and by using the reagent composition, the two medicine contents and the related substances in the tazarotene-betamethasone cream can be simultaneously separated and determined through high performance liquid chromatography. According to the present invention, the method has good reproducibility, the solvent peak does not interfere with the determination of the two medicine contents and the related substances in the tazarotene-betamethasone cream during the detection, the two medicines and the related substances in the tazarotene-betamethasone cream can be effectively separated, the separation degree is more than 2.0, the detection result is accurate and reliable, and the important significance is provided for the achievement of the quality control of the tazarotene-betamethasone cream.

The present invention provides a method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid. This invention is especially useful for treating psoriasis.

The invention relates to a compound external medicine for treating acne. It is characterized in that: the matrix carrier of the compound external drug contains the following two effective active ingredients (weight percentage): 0.01-2% of tazarotene, and 0.25-5% of antibacterial drugs; the effective active ingredient contained in the compound external drug After mixing with a base carrier, it forms a cream or gel or a liniment or film. The advantage of the present invention is that: the present invention contains two main components of retinoic acid and antibacterial for treating acne in the form of a compound preparation, so as to simultaneously exert three (and above) curative effects (dissolving horn plugs, regulating keratinization, Antimicrobial, anti-inflammation, secondary factors to reduce sebum secretion, etc.), played a complementary and synergistic effect in pharmacology.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

A composition for the treatment of acne includes hydrolyzed Psoralea corylifolia, containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In various implementations, the composition is a water-based acne gel or a water-based cleanser. In a specific implementation, a composition includes Bakutrol™, which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid, benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.

The invention provides a method for preparing tazarotene without copper iodide. Palladium catalysts and triphenylphosphine are added into specific organic solvents and stirred, replacement in nitrogenis performed, 4, 4-dimethyl thiochroman-6-radical-acetylene, 6-chloro-ethyl nicotinate and acid-binding agents are added to perform reaction. The method is environmentally friendly, the catalysts areeasily recycled, and waste water containing heavy metal is not generated. Compared with the prior art, the method is short in reaction time and reaction temperature. A product prepared by the methodis high in yield and purity and stable in quality.

The invention discloses an ointment for lowering clinical application side effects of tazarotene, belonging to the technical field of external ointments. The ointment is proportionally composed of a component A and a component B, wherein the component A is 1% tazarotene cream, and the component B is a Chinese herbal medicine extract. The clinical test proves that the ointment can obviously enhance the verruca plantaris treatment effect, and can also obviously lower the side effects in clinical application.

The present invention relates to a method of treating acne or psoriasis by topically administering Tazarotene substantially free of dimer impurity of formula 4,4-dimethyl-6-[4-(4,4-dimethylthiochroman-6-yl)-buta-1,3-diynyl]-thiochroman.

The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.

The invention provides a lipid complex of tazarotene and clindamycin phosphate. The lipid complex is prepared mainly by utilizing synthetic phospholipids and stearamide, is wrapped with tazarotene and is further mixed with the clindamycin to prepare cream and gel which are mainly used for treating acne vulgaris. The lipid complex is simple in preparation technique, and the stability of pharmaceuticals can be ensured in the preparation process; compared with the common cream and gel, the lipid complex has the advantages that the skin medicine retention volume is higher, the content of medicine in local skins can be increased, and the therapeutic index can be improved.

The invention belongs to the field of pharmacy and particularly relates to a pharmaceutical composition for treating hyperproliferative skin disease and a preparation of the pharmaceutical composition. The pharmaceutical composition comprises the following components by weight percent: 0.001-0.01% (W / W) of calcipotriene, 0.05-2% (W / W) of tazarotene and 0.05-2% (W / W) of adrenocortical hormone.

A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.

The invention provides a pharmaceutical composition for treating psoriasis, and its preparation forms include ointment and gel. The pharmaceutical composition contains 0.05%-0.5% (w / w) of tazarotene, 0.05%-2.5% (w / w) of adrenocorticosteroids and other pharmaceutically acceptable auxiliary agents. The adrenocortical hormone drug is preferably betamethasone dipropionate. The pharmaceutical composition of the invention has remarkable curative effect on psoriasis and good safety.

The invention discloses a tazarotene gelata and a preparation method thereof. The preparation is prepared form the active ingredient tazarotene and auxiliary materials. The auxiliary materials include methyl cyclodextrin and sodium alginate. The preparation method includes: dissolving methyl cyclodextrin in water, adding a prescribed amount of quantity of tazarotene, conducting stirring for dissolving so as to obtain a solution I; dissolving sodium alginate and a bacteriostatic agent in water to obtain a solution II; and mixing the two solutions and stirring the mixture evenly, thus obtaining the gelata. The tazarotene gelata provided by the invention has the advantages of simple preparation process, good gel stability, few variety of auxiliary materials, and easy coating.

The present invention belongs to the field of analytical chemistry, and relates to a method for separation and determination of two medicine contents and related substances in a tazarotene-betamethasone cream. According to the method, a reagent composition for solid-liquid separation and determination of two medicine contents and related substances in a tazarotene-betamethasone cream comprises an acidic aqueous solution system and acetonitrile, wherein the acidic aqueous solution system comprises an acidic additive, methanol and water; and by using the reagent composition, the two medicine contents and the related substances in the tazarotene-betamethasone cream can be simultaneously separated and determined through high performance liquid chromatography. According to the present invention, the method has good reproducibility, the solvent peak does not interfere with the determination of the two medicine contents and the related substances in the tazarotene-betamethasone cream during the detection, the two medicines and the related substances in the tazarotene-betamethasone cream can be effectively separated, the separation degree is more than 2.0, the detection result is accurate and reliable, and the important significance is provided for the achievement of the quality control of the tazarotene-betamethasone cream.

The invention provides a lipid complex of tazarotene and clindamycin phosphate. The lipid complex is prepared mainly by utilizing synthetic phospholipids and stearamide, is wrapped with tazarotene and is further mixed with the clindamycin to prepare cream and gel which are mainly used for treating acne vulgaris. The lipid complex is simple in preparation technique, and the stability of pharmaceuticals can be ensured in the preparation process; compared with the common cream and gel, the lipid complex has the advantages that the skin medicine retention volume is higher, the content of medicine in local skins can be increased, and the therapeutic index can be improved.

The present invention relates to compound 13-hexyl berberine hydrochloride and its congener 13-hexyl palmatine hydrochloride to prepare external skin anti-allergic, inflammatory, eczema, dermatitis and other skin diseases and anti-immune, inflammatory and proliferative drugs Uses of psoriasis medications. At the same time, because of its antibacterial activity, it also has a good therapeutic effect on eczema and dermatitis associated with infection. The external application of cream with 13-hexylberberine hydrochloride or 13-hexylpalmatine hydrochloride as the active ingredient has similar therapeutic effect on psoriasis as that of intermediate-acting corticosteroids and chemical antipsoriatic drug tazarotene, but not It can cause adverse reactions such as corticosteroids, and its simple and compound formulations should have unique effects in the treatment of psoriasis.